查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2084957

屍檢和病理檢測市場：按檢測類型、檢體類型、應用和最終用戶分類－2026-2032年全球市場預測

Anatomic Pathology Testing Market by Test Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，屍檢病理檢測市場將成長至 750.1 億美元，複合年成長率為 6.60%。

主要市場統計數據
基準年 2025 479.2億美元
預計年份：2026年 510億美元
預測年份 2032 750.1億美元
複合年成長率 (%) 6.60%

屍檢病理學是基於組織的診斷的基礎，它結合了組織病理學、細胞病理學、免疫組織化學、原位雜合反應和分子病理學，指南臨床決策。該市場與癌症檢測、腫瘤分類、分期、治療選擇和治療後後續觀察密切相關，在腫瘤診療路徑和精準醫療中發揮至關重要的作用。

全球癌症負擔日益加重、切片檢查使用量不斷成長、伴隨診斷需求增加以及數位病理學的普及，都進一步推動了相關需求。根據國際癌症研究機構（IARC）統計，2022年全球新增癌症病例約2,000萬例，癌症死亡病例約970萬例。隨著人口成長和老化，預計到2050年，癌症病例數將顯著增加。因此，醫院、實驗室和大學附屬醫院對高品質的屍檢病理檢測、快速出具結果、標準化報告以及對檢驗生物標記的解讀有著持續的需求。

解剖病理學領域的變革性變化

屍檢病理學領域正從以顯微鏡為中心的傳統工作流程轉向整合化、數據豐富的診斷生態系統。檢查室正優先推進組織處理、條碼管理、切片掃描、影像管理以及與實驗室資訊系統 (LIS) 整合等方面的自動化，以減少人為操作差異，提高可追溯性，並支援符合認證標準的品管。此外，數位化病理學的應用使得遠距會診、專家評審、腫瘤委員會協作以及跨多個地點的工作量分配成為可能。

人工智慧對病理檢測的累積影響

人工智慧正透過增強切片審查、病例分診、品管和定量生物標記評估，對整個屍檢病理價值鏈產生累積影響。獲得監管機構批准的數位病理學和人工智慧工具正在擴大臨床應用的證據基礎，尤其是在支持腫瘤檢測、有絲分裂計數、前列腺切片檢查審查、乳房病理學和免疫組織化學評分方面。

關於屍檢病理學的關鍵區域見解

隨著中國、印度、日本、韓國、澳洲和東南亞國家加大對癌症篩檢、三級醫療、病理學培訓和數位醫療基礎設施的投資，亞太地區正在蓬勃發展。該地區龐大的人口基數和非傳染性疾病負擔日益加重，推動了對組織病理學、細胞病理學、免疫組織化學、分子病理學和遠距醫療諮詢的需求。北美地區仍然是一個成熟的高價值地區，這得益於其強大的腫瘤檢測量、符合CLIA標準的檢查室、CAP認證、先進的伴隨診斷技術、綜合癌症中心以及對數位病理學的早期應用。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東協地區，癌症發生率上升、私立醫院投資增加、醫療旅遊以及區域數位醫療舉措推動了對組織病理學檢測、細胞病理學、免疫組織化學和數位化諮詢的需求。在海灣合作理事會（GCC）地區，政府主導的醫療改革、腫瘤中心和三級醫療機構的建設以及國際認證正在推動病理學現代化，從而提高了對先進組織病理學和伴隨診斷的需求。歐盟是重要的監管力量，其體外醫療設備法規（IVDR）提高了對整體解剖病理學和分子病理學工作流程中檢測性能、文件記錄、上市後監管和檢查室自建檢測（LDT）的期望。

對主要解剖病理學市場關鍵國家的洞察

美國憑藉大規模參考實驗室、大學附屬癌症中心、FDA批准的數位病理系統、CLIA監管、CAP認證的工作流程以及生物標記在腫瘤學領域的廣泛應用，在先進的解剖病理學檢測方面處於領先地位。加拿大受益於系統化的癌症診療、公共醫療保險覆蓋和經認證的檢查室品管，同時也在努力解決區域間在反應時間和檢測結果獲取方面的差異。墨西哥和巴西正在擴展私人診斷網路、腫瘤服務和免疫組織化學能力，但在公共部門的可及性、報銷一致性和病理學亞專科的可用性方面仍然存在不平衡。

為行業領導者提供的實用建議

產業領導者應優先考慮端到端工作流程的現代化，包括檢體追蹤、自動化組織處理、數位切片掃描、與實驗室資訊系統 (LIS) 的整合、符合 DICOM 標準的影像處理以及安全的雲端或混合儲存。投資決策應與可衡量的結果掛鉤，例如更快的檢測結果返回時間、更高的診斷一致性、病理學家的工作效率、品質指標、更少的重複檢測以及更有效率的腫瘤學會議。

基於證據的市場分析調查方法

本研究所採用的方法結合了二手資料研究、結構化的原始研究結果和分析三角驗證。主要資訊來源包括世界衛生組織和國際癌症研究機構的癌症統計數據、經濟合作暨發展組織和世界銀行的健康指標、美國食品藥品監督管理局的醫療設備資料庫、美國醫療保險和醫療補助服務中心和臨床實驗室改進修正案的指南、美國病理學家協會的認證標準、ISO 15189品質原則、歐洲藥品資料庫和歐盟體外診斷醫療設備審查和歐盟體外診斷醫療儀器法規的相關文件、公共衛生和醫療管理資料庫的相關文件、現有研究管理資料庫的相關文件、醫療管理資料庫。

結論：屍檢病理學的未來。

屍檢病理市場正進入一個新階段，其特點是癌症負擔日益加重、精準腫瘤學、數位病理學以及人工智慧驅動的工作流程最佳化。基於組織的診斷仍然至關重要，因為治療方案的選擇、分期、預後和生物標記的確認仍然依賴高品質的病理學解讀。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：屍檢病理檢測市場：依檢測類型分類

  • 數位病理學
    • 影像分析軟體
    • 幻燈片掃描儀
  • 蘇木精-伊紅染色
  • 免疫組織化學
    • 單株抗體
    • 多株抗體
  • 分子病理學
    • 螢光原位雜合反應
    • 次世代定序
    • 聚合酵素鏈鎖反應
  • 特殊染色
    • 高碘酸鹽-雪夫染色
    • 銀染料
    • 三色染色

第8章：屍檢病理檢測市場：依檢體類型分類

  • 細胞學檢體
  • 冰凍切片
  • 組織切片檢查

第9章：解剖病理學檢測市場：按應用領域分類

  • 遺傳性疾病
    • 染色體異常
    • 單基因疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 腫瘤學
    • 乳癌
    • 肺癌
    • 攝護腺癌

第10章：屍檢和病理檢測市場：按最終用戶分類

  • 診斷檢查室
  • 醫院
  • 研究機構

第11章：屍檢和病理檢測市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：屍檢病理檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：屍檢和病理檢測市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Abcam plc
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company
  • BioGenex Laboratories Inc.
  • Bio SB Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Hamamatsu Photonics KK
  • Hologic Inc.
  • Indica Labs LLC
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Leica Biosystems
  • Merck KGaA
  • NeoGenomics Laboratories Inc.
  • PerkinElmer Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Sakura Finetek USA Inc.
  • Sonic Healthcare Limited
  • Synlab Holding GmbH
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436901066173

The Anatomic Pathology Testing Market is projected to grow by USD 75.01 billion at a CAGR of 6.60% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.92 billion
Estimated Year [2026] USD 51.00 billion
Forecast Year [2032] USD 75.01 billion
CAGR (%) 6.60%

Anatomic pathology testing is the foundation of tissue-based diagnosis, combining histopathology, cytopathology, immunohistochemistry, in situ hybridization, and molecular pathology to guide clinical decisions. The market is closely linked to cancer detection, tumor classification, staging, treatment selection, and post-treatment surveillance, making it essential to oncology care pathways and precision medicine.

Demand is being reinforced by the rising global cancer burden, expanded biopsy utilization, companion diagnostic requirements, and broader adoption of digital pathology. According to the International Agency for Research on Cancer, the world recorded about 20 million new cancer cases and 9.7 million cancer deaths in 2022, with cases expected to rise substantially by 2050 as populations grow and age. This creates sustained need for high-quality anatomic pathology testing, faster turnaround times, standardized reporting, and validated biomarker interpretation across hospitals, reference laboratories, and academic medical centers.

Transformative Shifts in the Anatomic Pathology Landscape

The anatomic pathology testing landscape is shifting from microscope-centric workflows toward integrated, data-rich diagnostic ecosystems. Laboratories are prioritizing automation in tissue processing, barcoding, slide scanning, image management, and laboratory information system connectivity to reduce manual variation, improve traceability, and support accreditation-ready quality management. Digital pathology adoption is also enabling remote consultation, subspecialty review, tumor board collaboration, and multi-site workload balancing.

A second major shift is the convergence of morphology with molecular and immuno-oncology testing. Pathologists increasingly interpret tissue architecture alongside biomarker results such as HER2, PD-L1, mismatch repair proteins, EGFR, ALK, ROS1, NTRK, and other therapy-linked markers. At the same time, reimbursement scrutiny, pathology workforce shortages, and stricter quality expectations are pushing laboratories to demonstrate clinical utility, analytical validity, data integrity, and operational efficiency.

Cumulative Impact of Artificial Intelligence on Pathology Testing

Artificial intelligence is creating cumulative impact across the anatomic pathology testing value chain by enhancing slide review, case triage, quality control, and quantitative biomarker assessment. Regulatory-cleared digital pathology and AI-enabled tools have expanded the evidence base for clinical implementation, particularly in tumor detection support, mitotic counting, prostate biopsy review, breast pathology, and immunohistochemistry scoring.

The strongest near-term value of AI is workflow augmentation rather than autonomous diagnosis. Human-in-the-loop models can help prioritize urgent cases, flag potential discrepancies, standardize scoring, and improve reproducibility for biomarkers such as Ki-67, HER2, ER, PR, and PD-L1. However, adoption requires local validation, bias assessment, cybersecurity controls, audit trails, data governance, and alignment with CAP, CLIA, ISO 15189, FDA, and EU IVDR expectations.

Key Regional Insights for Anatomic Pathology Testing

Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and Southeast Asian countries invest in cancer screening, tertiary hospitals, pathology workforce development, and digital health infrastructure. The region's large population base and rising noncommunicable disease burden are increasing demand for histopathology testing, cytopathology, immunohistochemistry, molecular pathology, and remote subspecialty consultation. North America remains a mature, high-value region supported by strong oncology testing volumes, CLIA-regulated laboratories, CAP accreditation, advanced companion diagnostics, integrated cancer centers, and early digital pathology adoption.

Europe is shaped by universal healthcare systems, structured cancer programs, national screening initiatives, and the EU IVDR, which is increasing compliance requirements for diagnostic assays, laboratory-developed tests, documentation, and post-market surveillance. Latin America shows growing demand in Brazil and Mexico as private diagnostic networks and oncology services expand, but access to subspecialty pathology remains uneven across public and rural healthcare settings. The Middle East is investing in advanced hospital networks, oncology centers, international accreditation, and medical tourism, particularly in GCC countries. Africa presents long-term growth potential as cancer diagnosis needs rise, although pathology capacity, trained workforce availability, specimen referral systems, and laboratory infrastructure remain critical constraints.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, rising cancer incidence, expanding private hospital investment, medical tourism, and regional digital health initiatives are supporting demand for histopathology testing, cytopathology, immunohistochemistry, and digital consultation. The GCC is advancing pathology modernization through government-backed healthcare transformation, oncology centers, tertiary hospital development, and international accreditation, strengthening demand for advanced tissue diagnostics and companion diagnostic readiness. The European Union is a major regulatory force because the IVDR raises expectations for assay performance, documentation, post-market surveillance, and laboratory-developed test justification across anatomic pathology and molecular pathology workflows.

BRICS countries represent a high-volume growth engine, combining large patient populations with expanding diagnostic infrastructure, oncology capacity, and public health investment, although access, reimbursement, workforce availability, and quality standardization vary considerably. G7 markets remain innovation leaders in digital pathology, AI validation, molecular oncology, companion diagnostics, laboratory automation, and evidence-based reimbursement models. NATO countries, with significant overlap in North America and Europe, benefit from resilient health systems, cross-border research networks, advanced laboratory quality frameworks, and strong adoption of interoperable health data standards.

Key Country Insights in Major Anatomic Pathology Markets

The United States leads in advanced anatomic pathology testing through large reference laboratories, academic cancer centers, FDA-cleared digital pathology systems, CLIA oversight, CAP-accredited workflows, and broad biomarker adoption in oncology. Canada benefits from organized cancer care, public health coverage, and accreditation-driven laboratory quality, while continuing to address regional turnaround-time and access gaps. Mexico and Brazil are expanding private diagnostic networks, oncology services, and immunohistochemistry capacity, although public-sector access, reimbursement consistency, and subspecialty pathology availability remain uneven.

In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize cancer pathway efficiency, national screening programs, digital pathology pilots, biomarker standardization, and compliance with evolving EU diagnostic regulations, while Russia maintains significant hospital-based demand despite procurement and modernization challenges. China is scaling pathology capacity across major hospitals and oncology centers, India is seeing growth from private laboratories, cancer hospitals, and molecular oncology networks, Japan emphasizes high-quality diagnostics and aging-related cancer demand, Australia supports accreditation-led pathology services and organized cancer care, and South Korea is advancing digital pathology, precision oncology, and high-throughput laboratory modernization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize end-to-end workflow modernization, including specimen tracking, automated tissue processing, digital slide scanning, LIS integration, DICOM-compatible imaging, and secure cloud or hybrid storage. Investment decisions should be tied to measurable outcomes such as turnaround time, diagnostic concordance, pathologist productivity, quality indicators, rework reduction, and tumor board efficiency.

Organizations should also build AI governance before deployment by defining validation protocols, intended use, human oversight, model monitoring, cybersecurity, and change-control processes. Strategic partnerships with oncology providers, pharmaceutical sponsors, academic centers, and payers can improve biomarker access and companion diagnostic readiness. Workforce resilience should be addressed through subspecialty networks, remote sign-out where permitted, continuing education, training programs, and standardized reporting templates aligned with recognized pathology guidelines.

Research Methodology for Evidence-Based Market Analysis

The research approach combines secondary research, structured primary insights, and analytical triangulation. Core sources include WHO and IARC cancer statistics, OECD and World Bank health indicators, FDA device databases, CMS and CLIA guidance, CAP accreditation standards, ISO 15189 quality principles, EMA and EU IVDR documentation, peer-reviewed pathology literature, public health agency publications, and regulatory databases.

Market interpretation is based on segmentation by test type, technology, application, end user, and geography without relying on market sizing or forecasting. Findings are validated through comparison of epidemiology trends, diagnostic utilization, regulatory developments, reimbursement signals, laboratory workflow evidence, quality standards, and technology adoption patterns. AI-related conclusions are limited to documented clinical, regulatory, and operational evidence to ensure data-backed, defensible insights.

Conclusion: The Future of Anatomic Pathology Testing

The anatomic pathology testing market is entering a new phase defined by cancer burden growth, precision oncology, digital pathology, and AI-assisted workflow optimization. Tissue-based diagnosis remains indispensable because treatment selection, staging, prognosis, and biomarker confirmation continue to depend on high-quality pathology interpretation.

Future leadership will favor organizations that combine clinical excellence with scalable technology, regulatory discipline, interoperability, and measurable value creation. Laboratories that modernize operations while maintaining pathologist oversight, quality assurance, validated AI use, and patient-centered reporting will be best positioned to strengthen performance across histopathology testing, cytopathology, molecular pathology, immunohistochemistry, and companion diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anatomic Pathology Testing Market, by Test Type

  • 7.1. Digital Pathology
    • 7.1.1. Image Analysis Software
    • 7.1.2. Slide Scanners
  • 7.2. Hematoxylin And Eosin Staining
  • 7.3. Immunohistochemistry
    • 7.3.1. Monoclonal Antibody
    • 7.3.2. Polyclonal Antibody
  • 7.4. Molecular Pathology
    • 7.4.1. Fluorescence In Situ Hybridization
    • 7.4.2. Next Generation Sequencing
    • 7.4.3. Polymerase Chain Reaction
  • 7.5. Special Staining
    • 7.5.1. Periodic Acid-Schiff Stain
    • 7.5.2. Silver Stain
    • 7.5.3. Trichrome Stain

8. Anatomic Pathology Testing Market, by Sample Type

  • 8.1. Cytology Samples
  • 8.2. Frozen Sections
  • 8.3. Tissue Biopsy

9. Anatomic Pathology Testing Market, by Application

  • 9.1. Genetic Disorders
    • 9.1.1. Chromosomal Disorders
    • 9.1.2. Single Gene Disorders
  • 9.2. Infectious Diseases
    • 9.2.1. Bacterial Infections
    • 9.2.2. Viral Infections
  • 9.3. Oncology
    • 9.3.1. Breast Cancer
    • 9.3.2. Lung Cancer
    • 9.3.3. Prostate Cancer

10. Anatomic Pathology Testing Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Anatomic Pathology Testing Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Anatomic Pathology Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Anatomic Pathology Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Abcam plc
  • 15.3. Agilent Technologies Inc.
  • 15.4. Becton, Dickinson and Company
  • 15.5. BioGenex Laboratories Inc.
  • 15.6. Bio SB Inc.
  • 15.7. Danaher Corporation
  • 15.8. Eurofins Scientific SE
  • 15.9. F. Hoffmann-La Roche AG
  • 15.10. Hamamatsu Photonics K.K.
  • 15.11. Hologic Inc.
  • 15.12. Indica Labs LLC
  • 15.13. Koninklijke Philips N.V.
  • 15.14. Laboratory Corporation of America Holdings
  • 15.15. Leica Biosystems
  • 15.16. Merck KGaA
  • 15.17. NeoGenomics Laboratories Inc.
  • 15.18. PerkinElmer Inc.
  • 15.19. Qiagen N.V.
  • 15.20. Quest Diagnostics Incorporated
  • 15.21. Sakura Finetek USA Inc.
  • 15.22. Sonic Healthcare Limited
  • 15.23. Synlab Holding GmbH
  • 15.24. Sysmex Corporation
  • 15.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMAGE ANALYSIS SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMAGE ANALYSIS SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMAGE ANALYSIS SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SLIDE SCANNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SLIDE SCANNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SLIDE SCANNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOXYLIN AND EOSIN STAINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOXYLIN AND EOSIN STAINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOXYLIN AND EOSIN STAINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POLYCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POLYCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POLYCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SPECIAL STAINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SPECIAL STAINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SPECIAL STAINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERIODIC ACID-SCHIFF STAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERIODIC ACID-SCHIFF STAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERIODIC ACID-SCHIFF STAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SILVER STAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SILVER STAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SILVER STAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRICHROME STAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRICHROME STAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRICHROME STAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYTOLOGY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYTOLOGY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYTOLOGY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FROZEN SECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FROZEN SECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FROZEN SECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHROMOSOMAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHROMOSOMAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHROMOSOMAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SINGLE GENE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SINGLE GENE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SINGLE GENE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 336. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 340. RUSSIA ANATOMIC PATHOLOG